Redcare Pharmacy Appoints Amazon Finance Veteran as New CFO

In a strategic move to strengthen its leadership team, Redcare Pharmacy has recruited a senior Amazon executive to helm its financial operations. The appointment comes as the online pharmacy navigates a significant corporate restructuring and works to reverse a substantial decline in its share price.

A Seasoned E-commerce Leader Takes the Financial Reins

Hendrik Krampe, formerly the Finance Director for Amazon’s European Marketplace business, is slated to become the Chief Financial Officer of Redcare Pharmacy effective December 1, 2025. Krampe brings to the role two decades of executive-level experience at major e-commerce firms, including previous tenures at both Amazon and eBay. This hiring signals a clear intent by Redcare to leverage expertise from a professional skilled in scaling digital business models and driving them toward profitability.

This leadership change occurs at a pivotal moment for the company. Redcare’s stock has plummeted by more than 52% since the start of the year, trading near its 52-week low. Despite this market performance, the company’s underlying business continues to exhibit robust expansion, presenting a central challenge: converting this vigorous growth into consistent, sustainable profits.

Operational Strength Contrasts with Market Performance

The current situation presents a paradox. On one hand, Redcare’s operational metrics are stronger than ever. The company reported a 25% surge in revenue for the third quarter of 2025, reaching 719.2 million euros. A primary growth engine has been its German prescription medication (Rx) business, which is seen as crucial for long-term profitability.

Perhaps more significantly, the company has achieved a turnaround in its earnings. Redcare posted an adjusted EBITDA of 17.1 million euros for Q3 2025, bringing the total for the first nine months of the year to 44 million euros. Management has reaffirmed its full-year guidance, projecting revenue growth exceeding 25%.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

This raises a critical question: why has the stock market failed to reward these tangible improvements? The answer may lie in lingering doubts about the durability of this profitability or in a broader market skepticism toward high-growth, yet still-maturing, business models operating in a challenging economic climate. This is precisely the area where the incoming CFO from Amazon is expected to make an impact.

Chairman’s Significant Share Purchase Sends a Signal

As many investors exit their positions, the Chairman of the Supervisory Board, Dr. Björn Söder, has made a notable demonstration of confidence. On November 11, 2025, he acquired 2,000 company shares for approximately 128,000 euros. Such insider purchases are traditionally interpreted as a potent bullish signal in financial markets, indicating that top leadership is willing to invest personal capital based on their belief in the company’s valuation and future prospects.

This move is particularly resonant during a period of intense stock price pressure, serving as a powerful endorsement of the company’s strategic direction and financial health, and suggesting that the market’s current appraisal is overly pessimistic.

Analyst Perspective: A More Balanced View

The Swiss investment bank UBS recently updated its assessment of Redcare Pharmacy, delivering a mixed message. While the bank upgraded its rating from “Sell” to “Neutral,” it simultaneously reduced its price target from 82 euros to 74 euros. The rationale provided was that following the steep decline since the beginning of the year, the stock’s risk-reward profile has become more balanced.

In other words, UBS no longer considers the shares to be fundamentally overvalued after their significant drop, but it does not yet see them as a clear buying opportunity.